Hipoglucemia

Ajoene is an organosulfur compound derived from garlic with well-documented antiplatelet activity. It directly interacts with the platelet fibrinogen receptor (glycoprotein IIb/IIIa), blocking fibrinogen binding and preventing aggregation. The Natural Medicines Comprehensive Database specifically identifies ajoene in garlic as having antiplatelet properties.

ALA reduces platelet aggregation and thrombotic risk through prostanoid and nitric oxide pathways. It shifts the eicosanoid balance toward anti-aggregatory mediators and reduces the probability of thrombotic events.

DHA and EPA from algal oil inhibit platelet activation and aggregation, reducing thrombotic risk. Clinical and in vitro studies confirm that omega-3 PUFAs inhibit platelet activation, lipoprotein oxidation, and pro-thrombotic eicosanoid production. At high doses (>3 g/day), algal oil can affect blood clotting, which is why the FDA sets an upper limit of 5 g combined DHA+EPA/day from supplements.

Allicin (diallyl thiosulfinate) is the primary bioactive organosulfur compound in garlic responsible for antiplatelet activity. It prolongs clotting time by inactivating thrombin and blocking fibrinogen-to-fibrin conversion. In vitro data show allicin-class thiosulfinates suppress human platelet aggregation and inhibit collagen-receptor platelet binding.

Isoquercitrin (the direct precursor and metabolite of AGIQ) belongs to a quercetin-class of flavonoids with documented antiplatelet properties in vitro and in animal models. Anti-anaphylactic cardiovascular studies show isoquercitrin blunts hemodynamic instability associated with massive mediator release. Quercetin inhibits arachidonic acid-mediated platelet aggregation. Human RCT evidence specific to AGIQ for thrombosis prevention is absent.

EPA and DHA from anchovies exert well-documented antithrombotic effects by inhibiting platelet aggregation, reducing thromboxane A2 synthesis, and improving blood flow. Clinical studies and meta-analyses confirm that omega-3 fatty acids reduce blood clotting tendency, with WebMD and Healthline both noting reduced stroke risk via blood clot reduction.

Andrographolide inhibits platelet aggregation in human platelet preparations in vitro, inhibiting both PAF-induced and thrombin-induced aggregation in a dose-dependent manner. A human study in 63 cardiac/cerebrovascular patients showed significant inhibition of ADP-induced platelet aggregation following A. paniculata extract administration.

A controlled human clinical trial in 38 metabolic syndrome patients found that 1–2 months of Aronia melanocarpa extract significantly inhibited platelet aggregation and reduced the overall potential for coagulation and clot formation. Fibrinogen concentrations were also reduced in a separate clinical study. In vitro data support direct antiplatelet activity via ADP-pathway inhibition.

Ashitaba chalcone XA inhibits platelet aggregation in vivo in mouse tail-bleeding models. Ashitaba exudate reduces PAI-1 (a prothrombotic plasminogen activator inhibitor) in obese, diabetic, and aging mouse models. The Springer Archives of Pharmacal Research review lists anti-thrombotic activity as a confirmed property of ashitaba extracts.

Mixed tocopherols including delta and gamma forms inhibit platelet aggregation in humans more effectively than alpha-tocopherol alone. A randomized human trial showed that mixed tocopherols (containing 40 mg delta-tocopherol daily) significantly reduced ADP-induced platelet aggregation via increased nitric oxide release. This anti-thrombotic effect supports the role of non-alpha tocopherols, including delta, in blood clot prevention.

Bilberry has documented antiplatelet and anticoagulant-potentiating properties. It inhibits platelet aggregation and may increase prothrombin time and partial thromboplastin time. These effects are clinically significant enough that Memorial Sloan Kettering and Drugs.com warn of potential bleeding interactions with anticoagulant and antiplatelet medications.

Fucoidan from F. vesiculosus shows strong antithrombin and anticoagulant activity in vitro by interacting with heparin cofactor II and antithrombin III. A study published in Oxford Academic confirmed antithrombotic activity in platelet tests. No human anticoagulant clinical trials have been conducted.

Bromelain from pineapple has documented anticoagulant and fibrinolytic properties. It prolongs prothrombin time and APTT, increases fibrin cleavage, and upregulates antithrombin III and plasminogen. A 2022 PMC study confirmed bromelain inhibited the coagulation cascade and promoted fibrinolytic activity in a NAFLD model through LC-MS/MS-verified protein expression changes.

DHA and EPA from marine sources including calamari oil have demonstrated antiplatelet and antithrombotic properties in multiple human studies. A meta-analysis of 15 RCTs provided evidence that omega-3 PUFAs inhibit blood platelet aggregation. Both DHA and EPA show dose-dependent inhibitory effects on platelet aggregation induced by multiple agonists.

In vitro studies using human platelet-rich plasma have demonstrated that Uncaria tomentosa extracts exhibit antiplatelet effects and thrombin inhibition. A 2020 PubMed-indexed study (PMID available via ScienceDirect) concluded that extracts show 'slight antiplatelet effects' and 'promising candidates for natural inhibitors of thrombin.' Traditional use for blood purification is also documented.

Catechins from green tea and other plant sources inhibit platelet aggregation through TXA2 suppression, calcium signaling modulation, and glycoprotein VI pathway inhibition. A 2022 systematic review confirmed catechin-rich green tea among herbs with RCT-demonstrated antiplatelet activity. EGCG is the most potent individual catechin.

Higher fibrinolytic activity documented in Thai populations has been attributed to regular daily cayenne pepper consumption. Capsaicin promotes fibrinolysis (clot dissolution) and has mild anticoagulant-like properties. ScienceDirect cites this population-level fibrinolytic observation as a noteworthy finding attributed to cayenne intake.

Chinese Salvia Root (Danshen, Salvia miltiorrhiza) is a classical TCM herb with documented antiplatelet and antithrombotic activity. Its active components inhibit platelet aggregation, exhibit antithrombin III-like activity, and a controlled pilot study showed danshen extracts reduced ischemic stroke recurrence. It is classified as a major interactor with anticoagulant and antiplatelet drugs.

A human clinical trial in metabolic syndrome patients found that short-term chokeberry extract supplementation significantly reduced platelet aggregation, clot formation potential, and fibrinolysis markers. In vitro studies confirm inhibition of thrombin activity. These effects are attributed to the polyphenol content, primarily anthocyanins.

Cocoa flavanols reduce platelet aggregation and augment antiplatelet drug effects. A 2022 pilot RCT (ECLAIR study) in coronary artery disease patients showed 30 g/day of 65% cocoa augmented clopidogrel's antiplatelet effect, reducing P2Y12 reaction units by 11.9%. Cocoa's antiplatelet activity operates via reduced thromboxane production and nitric oxide pathways.

Cod liver oil's EPA and DHA reduce platelet aggregation and thrombus formation by competing with arachidonic acid for thromboxane A2 synthesis. Human studies document prolonged bleeding time with CLO supplementation. These antiplatelet effects contribute to cardiovascular protection.

Forskolin inhibits platelet aggregation through cAMP-mediated mechanisms, demonstrated in human platelet in vitro experiments. It antagonizes platelet-activating factor and thromboxane A2-driven platelet activation. Laboratory evidence is well-established but human clinical trials for thrombosis prevention have not been conducted.

Cranberry and its A-type proanthocyanidins inhibit platelet aggregation in human studies. A 2022 systematic review confirmed cranberry among herbs/foods with RCT-demonstrated platelet aggregation inhibition. Cranberry polyphenols modulate platelet activation pathways relevant to cardiovascular clot prevention.

Curcumin is the polyphenol bioactive in turmeric with well-documented antithrombotic, anticoagulant, and fibrinolytic properties. It inhibits platelet aggregation via arachidonic acid and TXA2 pathway suppression. A 2017 PubMed review comprehensively documented its mechanisms in hemostasis, anticoagulation, and fibrinolysis.

Curcuminoids are the polyphenolic compounds of turmeric (curcumin, demethoxycurcumin, bisdemethoxycurcumin) collectively responsible for antithrombotic effects. Curcumin is the primary active curcuminoid inhibiting platelet aggregation via arachidonic acid metabolism suppression and multiple platelet activation pathways. A 2017 PubMed review documented the full mechanistic spectrum.

Alpha-tocopherol inhibits platelet aggregation in vitro and in vivo through protein kinase C–dependent and oxidative stress–mediated mechanisms, and at high doses can interfere with vitamin K–dependent coagulation factors. The antiplatelet effect has been demonstrated in human platelet studies, though in vivo clinical impact at moderate supplemental doses is inconsistent.

Daidzein — produced via gut metabolism of daidzin — has documented antithrombotic activity, inhibiting platelet aggregation and blood viscosity in animal and some human studies of kudzu preparations. The 2024 CVD review confirmed antithrombotic effects in preclinical settings.

Danshen (Salvia miltiorrhiza) is a classical TCM herb with well-documented antiplatelet and antithrombotic activity. Its active components—danshensu, salvianolic acids, and tanshinones—inhibit platelet aggregation and exhibit antithrombin III-like activity. A controlled pilot study showed danshen extracts reduced ischemic stroke recurrence.

DHA is an omega-3 fatty acid with documented antiplatelet properties; it dose-dependently inhibits platelet aggregation and reduces integrin αIIbβ3 expression on platelet membranes. It is incorporated into platelet phospholipids where it alters membrane fluidity and reduces platelet activation responses. Evidence comes from in vitro studies, RCTs of combined EPA/DHA, and systematic reviews.

Docosahexaenoic acid dose-dependently inhibits platelet aggregation and reduces αIIbβ3 integrin expression on platelet membranes. It is incorporated into platelet phospholipids where it alters membrane fluidity and reduces activation responses. Evidence includes in vitro studies, RCTs of combined EPA/DHA supplementation, and systematic reviews.

Dong Quai (Angelica sinensis) contains coumarin constituents (ferulic acid, osthole) that inhibit platelet aggregation by blocking thromboxane A2 production and prolonging prothrombin time. Animal studies confirm significant PT prolongation without altering warfarin pharmacokinetics. It is listed among natural products with direct anticoagulant effects in authoritative medical literature.

DPA inhibits platelet aggregation more efficiently than either EPA or DHA, acting through lipoxygenase-derived oxylipins and COX-1 inhibition. It integrates into platelet membranes and shifts eicosanoid balance toward anti-thrombotic mediators. These antiplatelet effects have been demonstrated in human platelet preparations and animal models.

EGCG is the most abundant and potent catechin in green tea with documented antiplatelet activity. It inhibits platelet aggregation by suppressing TXA2 synthesis, modulating calcium signaling, and reducing collagen-receptor platelet activation. A 2022 systematic review included green tea/EGCG among herbs with RCT-demonstrated platelet aggregation inhibition.

EPA inhibits platelet aggregation, reduces thromboxane A2 synthesis, decreases mean platelet volume, and lowers blood viscosity, collectively reducing thrombotic risk. Multiple RCTs and a seminal human study with purified EPA demonstrated significant reductions in platelet aggregation and hemostatic markers.

EPA is the primary omega-3 responsible for fish oil's antiplatelet activity, competing with arachidonic acid to reduce TXA2 and increasing nitric oxide release. High-dose purified EPA (icosapent ethyl 4 g/day) is FDA-approved for cardiovascular risk reduction and demonstrated 25% relative risk reduction in the REDUCE-IT trial.

Asafoetida contains coumarins that are documented to inhibit blood clotting and thin the blood. Pharmacological reviews state it 'thins the blood and lowers blood pressure.' Coumarins in asafoetida may also enhance the activity of anticoagulant drugs such as warfarin.

Ferulic acid possesses documented anti-platelet and anti-thrombotic properties, recognized as a core pharmacological activity. It inhibits platelet aggregation and has been classified as anti-thrombotic in multiple pharmacological reviews. These properties contribute to its cardiovascular protective profile.

Feverfew and its active compound parthenolide inhibit platelet serotonin release and platelet aggregation in vitro. Authoritative cardiovascular literature (JACC) documents these antiplatelet effects. In vitro antiplatelet activity has not been confirmed in human clinical trials, but feverfew is listed among supplements with potential blood-thinning properties requiring preoperative cessation.

Fish oil (EPA and DHA) has well-recognized antiplatelet effects documented in multiple RCTs. EPA and DHA are incorporated into platelet membranes, altering fluidity and reducing TXA2 production and platelet aggregation. A 2024 systematic review of 11 RCTs (n=120,643) confirmed antiplatelet activity without significant overall bleeding risk increase at standard doses.

Flaxseed has been shown to reduce platelet stickiness, and its ALA content may contribute to anti-thrombotic effects. RxList and peer-reviewed reviews note that flaxseed makes platelets less sticky, potentially lowering atherosclerosis and thrombosis risk.

Forskolin inhibits platelet aggregation in vitro via cAMP elevation in platelets, reducing thromboxane A2-mediated activation. Platelet aggregation inhibitory activity is listed as a confirmed pharmacological property in peer-reviewed literature.

Fucoidan is a sulfated polysaccharide from brown algae with heparin-like anticoagulant activity, inhibiting thrombin, reducing platelet aggregation, and prolonging APTT and PT. An authoritative PubMed review specifically identifies fucus (fucoidan source) as having heparin-like antithrombotic activity. Multiple in vitro and animal studies support its antithrombotic effects.

Fungal proteases from multiple Aspergillus species exhibit documented fibrinolytic activity in vitro and in early human/animal studies, degrading fibrin and activating hemostasis-related proteins. Aspergillus oryzae-derived CA-7 was used clinically as a thrombolytic agent in case reports. Most current evidence for fibrinolytic activity of supplemental-grade oral fungal protease is indirect.

In animal studies, γT inhibited platelet aggregation and delayed arterial thrombus formation more potently than α-tocopherol, and reduced LDL oxidation and superoxide generation. A human study showed γT supplementation prevented exercise-induced increases in coagulation and platelet aggregation in sedentary individuals. Mechanistic evidence in humans is preliminary.

Geniposide and genipin from Gardenia jasminoides have documented antiplatelet aggregation and antithrombotic activities in animal models. Aqueous extract of G. jasminoides significantly inhibited arterial thrombosis in animal models, and geniposide inhibited platelet aggregation in earlier in vitro studies.

Geniposide from Gardenia jasminoides has demonstrated antithrombotic activity and inhibition of platelet aggregation in preclinical studies, as documented in multiple pharmacological reviews. This is listed among geniposide's established pharmacological activities in peer-reviewed literature. Human clinical evidence is absent.

Garlic contains allicin and organosulfur compounds that inhibit platelet aggregation through multiple pathways including thromboxane synthesis suppression and collagen-receptor blocking. A randomized clinical trial of 62 healthy volunteers found garlic tablets (1,250 mg) produced antiplatelet effects comparable to low-dose aspirin. Multiple authoritative reviews cite garlic as having well-established antiplatelet and antithrombotic properties.

Garlic inhibits platelet aggregation via multiple mechanisms including COX inhibition, thromboxane A2 suppression, cAMP/cGMP elevation, and nitric oxide stimulation. A systematic review of 12 RCTs (595 participants) and the Linus Pauling Institute review of 10 RCTs confirm modest but significant antiplatelet effects in human subjects.

Ginger contains gingerols and shogaols that inhibit platelet aggregation by suppressing arachidonic acid metabolism and TXA2 synthesis. A systematic review confirmed antiplatelet effects across multiple in vitro and in vivo studies. Recent PubMed research identified ginger-derived 6-paradol and 10-gingerol as novel vitamin K epoxide reductase (VKOR) inhibitors extending anticoagulant mechanisms.

Ginkgo biloba contains ginkgolides that inhibit platelet-activating factor (PAF), reducing platelet aggregation. A 2025 PLoS ONE analysis found ginkgo biloba interactions were significantly associated with bleeding risk (OR 1.08, p<0.001) and a large chart review (n=807,399) found its combination with warfarin increases major bleeding risk. Evidence on standalone antiplatelet efficacy in controlled trials is mixed.

Ginseng has documented in vitro platelet aggregation inhibitory effects via ginsenosides. However, RCTs show ginseng does not affect or may decrease warfarin's anticoagulant effect, and a case-crossover study showed no association with bleeding, reflecting complex and inconsistent antithrombotic activity in clinical settings.

Ginsenosides are the active triterpenoid saponins in ginseng responsible for its in vitro platelet aggregation inhibitory effects. Multiple in vitro studies demonstrate ginsenoside-mediated inhibition of platelet aggregation. However, clinical translation to blood clot prevention in humans has shown inconsistent results in controlled trials.

GLA supplementation significantly reduces platelet aggregation and serum thromboxane B2—a platelet activator—while increasing bleeding time and vascular prostacyclin, a profile consistent with reduced thrombotic risk. A 4-month clinical study in hyperlipidemic patients documented ~45% reduction in platelet aggregation with GLA.

Grape seed GSE and resveratrol both possess antiplatelet properties documented in human and animal studies. GSE reduced platelet reactivity in male smokers compared to placebo in a clinical study. Resveratrol suppresses platelet aggregation in animal models and carries anticoagulant-interaction warnings from major cancer centers. Clinical evidence is mostly from secondary endpoints; dedicated antithrombotic RCTs are lacking.

GSE has demonstrated antiplatelet and anticoagulant activity in in vitro models. OPCs inhibit ADP-induced platelet aggregation, prolong coagulation times (APTT, PT, TT), inhibit thrombin amidolytic activity, and improve blood flow. A human study in postmenopausal women and in vitro research support these platelet-inhibitory effects.

Green tea catechins (particularly EGCG) inhibit platelet aggregation in vitro and ex vivo. A 2022 systematic review confirmed green tea among herbs with demonstrated platelet aggregation inhibition in controlled study designs. Green tea catechins modulate thromboxane A2 synthesis and platelet activation pathways.

Guarana aqueous extract demonstrates distinct platelet aggregation inhibition both in vitro and in vivo, established in multiple publications. The active compounds are catechins, epicatechins, and their dimers in complex with caffeine. This antiplatelet activity reduces thromboxane synthesis and is potent enough to potentially interact with anticoagulant medications.

Guggul has demonstrated anti-platelet and pro-fibrinolytic activities in human clinical studies. A study in coronary artery disease patients found significant reductions in platelet adhesive index and increases in fibrinolytic activity after 30 days. Guggulsterones have also been shown to inhibit platelet aggregation in laboratory studies.

Hawthorn contains oligomeric proanthocyanidins and flavonoids that inhibit platelet aggregation in vitro. A 2022 systematic review confirmed hawthorn among herbs with demonstrated platelet aggregation inhibition in controlled study designs. Hawthorn flavonoids modulate TXA2 synthesis and oxidative stress pathways relevant to platelet activation.

When metabolized, IHN releases niacin, which inhibits a clotting-related protein (fibrinogen) and may enhance fibrinolysis, thereby reducing clot formation risk. WebMD and RxList note that inositol nicotinate 'breaks up a protein needed for the clotting of blood.' The Holti 1979 Raynaud's trial also proposed enhanced fibrinolysis as part of IHN's mechanism. However, formal anticoagulant RCTs specific to IHN are lacking; the relationship is primarily mechanistic and inferred from niacin pharmacology.

Kale is among the richest dietary sources of vitamin K1, which is essential for the carboxylation and activation of clotting factors II, VII, IX, and X. Adequate vitamin K1 is required for normal hemostasis. Vitamin K1 from foods like kale maintains, rather than promotes, healthy clotting—it does not increase thrombosis risk beyond physiological normal levels.

Fucoidan, a sulfated polysaccharide found in kelp, has demonstrated anticoagulant and antithrombotic activity in human studies. A pilot clinical study in 24 participants showed fucoidan extended clotting time in humans. Memorial Sloan Kettering confirms that dietary fucoidan modulates platelet aggregation via anti-thrombotic effects in humans.

L-arginine-derived nitric oxide inhibits platelet aggregation and reduces leukocyte adhesion, both of which are prothrombotic processes. Decreased platelet aggregation has been directly observed in human studies. Clinical evidence is strongest for endothelial dysfunction populations (hypercholesterolemia, peripheral vascular disease) where NO bioavailability is impaired.

Lumbrokinase is a group of fibrinolytic enzymes from earthworms that specifically degrade fibrin to prevent and dissolve blood clots. A 2023 meta-analysis of over 3,000 ischemic stroke patients found lumbrokinase plus aspirin significantly reduced stroke recurrence. It has been used clinically in China for decades for cardiovascular and cerebrovascular thrombotic conditions.

Anti-platelet and anticoagulant activities are listed among marjoram's documented pharmacological properties in peer-reviewed reviews. In vitro and preclinical evidence supports inhibition of platelet aggregation, though no human clinical trials have been conducted.

Nattokinase is a fibrinolytic enzyme derived from Bacillus subtilis during soybean fermentation (natto). Multiple human clinical studies confirm it retains fibrinolytic and anticoagulant activity after oral administration, reducing fibrinogen, factor VII, and factor VIII. A 2015 Scientific Reports study demonstrated measurable thrombolytic and anticoagulation effects from a single oral dose. It is undergoing Phase II clinical trials for atherothrombotic prevention.

Nattokinase directly cleaves fibrin and activates plasminogen to plasmin, producing dual-pathway fibrinolytic and anticoagulant effects measurable in human subjects after a single oral dose. Human studies demonstrate reductions in coagulation factors VII, VIII, and fibrinogen, and increases in antithrombin and fibrin degradation products.

Olive polyphenols, particularly oleocanthal, have demonstrated antiplatelet effects in a human RCT. Oleocanthal-rich extra-virgin olive oil demonstrated acute anti-platelet activity in healthy men. Oleuropein and related compounds also inhibit platelet-aggregating cAMP phosphodiesterase. Anti-thrombotic effects are cited in pharmacological reviews of olive polyphenols.

Olive oil polyphenols—particularly hydroxytyrosol, oleuropein, and oleocanthal—inhibit platelet aggregation through multiple mechanisms in both in vitro and human clinical studies. EVOO boosts apoA-IV, which counteracts post-prandial platelet activation. A human study using hydroxytyrosol-rich extract demonstrated a 47% reduction in thromboxane B2 after 4 days.

Omega-3 polyunsaturated fatty acids (EPA and DHA) have well-established antiplatelet and anticoagulant properties documented in multiple RCTs and systematic reviews. They reduce TXA2 production, inhibit platelet aggregation, and modulate thrombin generation. A systematic review of 11 RCTs (n=120,643) confirmed antiplatelet activity without significant overall bleeding risk increase.

Onion peel extract and its quercetin content significantly inhibit platelet aggregation, the primary cellular event in thrombotic clot formation. The mechanism involves COX-1 and thromboxane A2 synthase inhibition alongside cyclic AMP elevation. These antiplatelet effects have been consistently demonstrated in multiple laboratory and animal studies.

Ethanol extract of Ophiopogon japonicus root (ROJ-ext) inhibits venous thrombosis in vivo and protects endothelial cells from anoxic injury. A fermented O. japonicus extract demonstrated antithrombotic and thrombolytic effects in carrageenan-induced thrombosis rat models. Ophiopogonin D is noted as an inhibitor of venous thrombosis in pharmacological literature.

Early peer-reviewed clinical studies, primarily from Italian research groups in the 1980s, reported that pantethine reduces platelet aggregation in dyslipidemic patients, an effect independent of its lipid-lowering actions. This antiplatelet activity is thought to derive from pantethine's modification of platelet phospholipid fatty acid composition via CoA-dependent pathways. The evidence base is limited to older, small studies without modern replication.

Parsley extracts demonstrate antithrombotic activity in vitro and in vivo, inhibiting platelet aggregation and reducing platelet adhesion. Apigenin is the primary bioactive responsible, acting via anti-aggregatory and anticoagulant mechanisms. Traditional use as an anticoagulant is also documented. Caution is warranted given parsley's high vitamin K content, which has opposing effects on systemic coagulation.

Parthenolide is the active sesquiterpene lactone from feverfew responsible for its antiplatelet effects. It inhibits platelet aggregation and serotonin release in vitro. A 1990 Journal of Pharmacy and Pharmacology study directly compared feverfew extract and parthenolide on platelet activity, confirming antiplatelet activity.

Pine bark extract (Pycnogenol) inhibits platelet aggregation, reducing thromboxane B2 formation and platelet reactivity. Clinical studies in smokers showed significant reduction of excessive platelet aggregation. This antithrombotic mechanism underlies its cardiovascular protective effects.

RCTs demonstrate Pycnogenol inhibits platelet aggregation and prevents venous thrombosis. The LONFLIT-FLITE randomized controlled trial showed prevention of venous thrombosis in long-haul flights. Pycnogenol's antithrombotic properties are based on inhibition of platelet aggregation and reduction of thromboxane.

Bromelain has well-characterized fibrinolytic and antithrombotic activities, including stimulation of plasminogen conversion to plasmin, inhibition of platelet aggregation, and interference with thrombin formation. These mechanisms were validated in early human cardiac studies, and the properties are consistently confirmed across reviews.

Multiple randomized, placebo-controlled, double-blind human trials have documented that policosanol inhibits platelet aggregation induced by arachidonic acid, collagen, and ADP. A dose-escalation RCT in 37 healthy volunteers showed progressively enhanced antiplatelet effects at 10–40 mg/day. A comparative study found policosanol's antiplatelet effects comparable to aspirin, with a different mechanism of action.

Pomegranate juice and its polyphenols (punicalagins, ellagic acid) inhibit platelet aggregation and reduce thrombus formation. A 2022 systematic review confirmed pomegranate juice among dietary interventions with demonstrated antiplatelet activity in controlled human studies. Pomegranate polyphenols modulate TXA2 synthesis and platelet activation.

Filipendula ulmaria extracts have demonstrated anticoagulant activity in both in vitro and in vivo pre-clinical studies, attributed to heparin-like and salicylate compounds. This is recognized in pharmacological reviews as a documented pharmacological activity, distinct from traditional use. No human trial data exist.

Quercetin and its metabolites (isorhamnetin, tamarixetin) potently inhibit platelet aggregation, suppress granule secretion, and reduce integrin αIIbβ3 function. Isoquercetin inhibited thrombosis in a murine laser-injury model. Quercetin synergistically enhances aspirin's antiplatelet effects, reducing aspirin IC50 by an order of magnitude.

Resveratrol inhibits platelet MAP kinase signaling, modulates oxidative stress and inflammatory cytokines, and has demonstrated antithrombotic effects relevant to venous thromboembolism in preclinical models. A 2025 systematic review confirmed resveratrol prevents and attenuates DVT and PE through antioxidant, anti-inflammatory, and anticoagulant mechanisms, though controlled human trials are lacking.

R. cordifolia has demonstrated anti-platelet activating factor (PAF) activity, inhibiting PAF-induced platelet aggregation on rabbit platelets in a published PubMed-indexed study (Tripathi et al., Indian J Exp Biol, 1993). Mollugin, a key constituent, also inhibits platelet aggregation triggered by collagen and arachidonic acid. Modern pharmacological reviews confirm 'anti-platelet aggregation' as an established pharmacological activity.

Rutin is among the most potent identified inhibitors of protein disulfide isomerase (PDI), an extracellular enzyme central to early thrombus formation. In animal models, orally administered rutin suppressed both platelet accumulation and fibrin generation. Human clinical translation is still pending, but mechanistic evidence is strong.

Safflower extracts and isolated HSYA have demonstrated anticoagulant and antiplatelet activity in vitro and in animal models, including inhibition of PAF- and ADP-induced platelet aggregation, prolongation of thrombin time, prothrombin time, and activated partial thromboplastin time. TCM has used safflower for over 2,500 years to prevent and dissolve blood clots.

Salvianolic acids (A and B) are water-soluble active components of Danshen (Salvia miltiorrhiza) with documented antiplatelet activity. Salvianolic acid A inhibits platelet aggregation via ERp57 protein disulfide isomerase inhibition. Multiple studies confirm salvianolic acids as key antithrombotic constituents of danshen.

Serratiopeptidase exhibits fibrinolytic activity documented in vitro (96.6% blood clot lysis at 300 U/mL after 4 hours at 37°C) and has been used clinically for thrombophlebitis (venous inflammatory disease with clot formation). A clinical study comparing SRP with seaprose S in venous inflammatory disease found 65% efficacy for SRP. However, no human RCT specifically for blood clot prevention has been identified.

Rutin from S. japonica exhibits antiplatelet and antithrombotic properties demonstrated in pharmacological studies. Sophoricoside and quercetin have been shown to inhibit platelet aggregation and ACE activity. Research shows rutin can prevent blood clot formation in animal models by inhibiting platelet collagen-stimulated aggregation.

SPMs, particularly resolvins, directly inhibit platelet aggregation and thrombus formation. In human CAD patients, omega-3-derived SPMs have been shown to promote clot remodeling. SPMs also facilitate the clearance of established clots (fibrinolytic remodeling) through macrophage-mediated mechanisms.

TMP/ligustrazine from CX is a well-documented antiplatelet and antithrombotic compound with mechanistic studies at the cellular and molecular level. It inhibits platelet aggregation under both low and high shear rates, suppresses platelet activation via the Akt signaling pathway, and protects endothelial cells from thrombotic injury. Clinical use in anticoagulation contexts is documented in China.

Tomato-derived lycopene and water-soluble tomato concentrate inhibit platelet aggregation via multiple mechanisms in vitro and in vivo. Lycopene inhibits phospholipase C activation and promotes cyclic GMP synthesis to reduce platelet activity. Fruitflow®, an EFSA-authorized water-soluble tomato extract, has a registered health claim for maintenance of normal platelet aggregation.

Turmeric's active compound curcumin inhibits arachidonic acid metabolism, reducing prothrombotic TXA2 and exerting antiplatelet and anticoagulant effects. A 2017 PubMed review documented curcumin's antithrombotic, anticoagulant, and fibrinolytic properties with defined molecular mechanisms. Authoritative sources list turmeric among the most common blood-thinning supplements.

Vitamin E has documented antiplatelet and anticoagulant properties; it inhibits platelet aggregation, antagonizes clotting factors, and at high doses acts as a vitamin K antagonist. Authoritative reviews list vitamin E (especially >400 IU) among the most common blood-thinning supplements. A case report documented coagulopathy from supplemental vitamin E through vitamin K-dependent factor deficiency.

Wasabi isothiocyanates—both 6-MSITC and allyl isothiocyanate—have demonstrated antiplatelet activity in vitro against human platelets, inhibiting aggregation induced by multiple agonists including collagen, ADP, arachidonic acid, and thrombin. 6-MSITC also reduces tissue factor expression in human endothelial cells. This activity is well-characterized mechanistically, though no clinical trials in humans have assessed thrombotic outcomes.

Red clover contains coumarin derivatives (including coumarin, medicagol, and coumestrol) that may exert mild anticoagulant effects. Historically it was considered a 'blood purifier' and used to promote circulation. There are case reports of bleeding events in users, and preclinical studies suggest it may enhance the effects of anticoagulant medications, but no robust clinical RCTs support blood clot prevention as an indication.

White willow bark salicin and its metabolites inhibit platelet aggregation, but to a measurably lesser extent than aspirin. This antiplatelet property has been documented in ex vivo studies and is recognized in clinical drug-interaction warnings. Clinical significance for thrombosis prevention in humans has not been established in trials.